A biotech startup committed to pioneering scalable and customizable cell production technology. At the forefront of innovation, its revolutionary CellFiber™ technology is advancing cell mass cultivation solutions to enable higher yields and product quality and ensure stability, predictability, and reproducibility of cells for cell and gene therapy applications.
A biotech company with proprietary RNA technology that can broadly applicable to rare and mass diseases.
A neuroscience company that focuses on the development of a small molecule drug for Alzheimer’s disease (AD). The compound is a potential first-in-class, oral inhibitor of selected ion channels that are thought to be pathologically and epidemiologically upstream of cognitive deficits and behavioral and psychological symptoms of dementia (BPSD).
A drug discovery company that uses single cell RNA sequencing technology to discover unique biological insights that were not identifiable otherwise. It combines proprietary scRNA methods and machine learning platform to identify underlining pathogenesis at a individual cell level.
A clinical-stage biotechnology company that develops small molecules modulating RNA modification enzymes (RMEs) for cancer and other diseases. The company innovates the frontier of therapeutics by merging the deep expertise of RME biology and a unique platform of RNA analysis.
reverSASP Therapeutics creates innovative new drugs for aging-related diseases targeting senescent cells. With its deep understanding of underlining biology of aging-related diseases, it focuses on Senescence-associated secretory phenotype, or SASP, as a drug target.
LUCA Science operates on the frontier of a novel branch of mitochondrial therapeutics applying its proprietary production technologies to various mitochondria related disease. Its mitochondrial transfer therapy restores function and biogenesis of cells with damaged or dysfunctional mitochondria as well as augments function of healthy cells.
Cellshoot Therapeutics is utilizing an innovative computational network analysis of the structure and function of intracellular protein pathways in order to search for novel drug discovery target molecules. The experts at Cellshoot are actively collaborating with drug development companies to discover and manufacture novel, highly effective, small molecule compounds in a short period of time.
Sonire develops non-invasive cancer treatment device using High-Intensity Focused Ultrasound (HIFU). HIFU creates cavitation bubbles that simultaneously visualize and treat the tissue, targeting with high accuracy by robot guidance and high efficiency by multi-channel/point irradiation, without requirement for anesthesia. Sonire applies this therapy for the treatment of intractable cancers, such as pancreatic cancer, and establish new treatment modalities in combination with drugs.
A10 Lab is developing a digital peer support community through its’ habituation app, connecting small groups of people to motivate and inspire each other through their health-related struggles. While A10 Lab initially focused on patients with diabetes, the app won top rankings and recognition used to encourage behavioral change in a broad range of metabolic illnesses or addiction with over 1 million users in Japan alone.
Modulus offers a revolutionary early-stage drug discovery platform capitalizing on industry-leading computational modeling. Modulus is striving to combine supercomputing with an informed network of scientific insight in focused biology and disease areas, ultimately leading to the generation of novel pipelines.
PuREC endeavors to treat metabolic bone diseases by employing highly purified, rapidly expanding mesenchymal stem cells (MSC). PuREC identified a unique set of high-grown MSC selection markers and offers an application that confers highly efficient and specified proliferation of MSC, while promoting an overall safer therapeutic option. PuREC entered clinical trials for hypophosphatasia and spinal cord stenosis in 2021.
Braizon Therapeutics is developing a drug delivery system (DDS) platform that employs novel nano-micelle technology with the ability to encapsulate drug substances of interest and to facilitate transcytosis by crossing the blood brain barrier (BBB). Building on years of academic research and development, Braizon’s DDS technology can readily deliver drugs with substantial efficiency and safety to the central nervous system (CNS).
Founded at the National Cancer Center in 2016, RIN Institute has developed diagnostic and therapeutic monoclonal antibodies (mAb) for colorectal cancer (CRC) by targeting unique disease- and tumor-specific antigens. RIN’s mAb and subsequent antibody drug conjugate (ADC) development pipeline exhibit high selectivity toward human tumor microenvironments.
NB Health Laboratory operates in the field of therapeutic monoclonal antibody (mAb) discoveries that are targeting G protein-coupled receptors (GPCR). Using a proprietary ‘discovery technology’ platform, NB Health Laboratory integrates a method to select mAb highly specified to the target and a rapid screening of B cells and plasma cells, delivering fast and localized modulation of GPCR activity.
Pentas developed and commercializes the world’s first medical device analysis software for Cerebral Aneurysm. Through their national research and development granted projects, the company also manufactures and sells virtual/intracranial stents and microcatheters.
Nano Innovation Laboratories develops beauty care products for aging concerns, aggregating 40 years of research achievements in nanotechnology and organic chemistry to their plant-derived products. Its hair dye uses state-of-the-art, super nano particle technology with rare and valuable botanical ingredients to deliver melanocyte stimulants, deep inside the follicles.
Fast Doctor was founded with a vision to enhance healthcare accessibility for elderly patients and for medical emergencies by providing 24 hour, at-home, medical care, 365 days a year. With their full-time availability and extensive triage process, they have become one of the largest overtime emergency platforms in the country.
Mediphone offers medical translation and payment solutions to medical institutions and foreign patients. It envisions to eliminate language barriers in healthcare and specialized medical care. It became an essential resource during the COVID-19 pandemic, helping to facilitate urgent medical needs for foreign patients in Japan.
VELDT offers IoT services, and develops software and data analytic technologies towards healthcare products, collaborating with consumer product brands. Its data-driven healthcare solution offers a modern, visceral approach to innovate the way we interact with technology and ultimately, generate positive momentum for human society and the global environment.
Yukashikado provides direct-to-consumer, at-home, nutrition diagnostic services, creating a highly personalized dietary improvement plan catered to each individual’s biological makeup. Its innovative urine-based nutrition testing technology allows for high sensitivity vitamin detection with utmost accuracy.
Modalis develops and operates a proprietary, engineered CRISPR technology which allows the precise modulation of gene expression. The foundational science rooted in academic achievements of CAS protein engineering from the University of Tokyo. Modalis’ gene modulation technology is developing safer and more efficient means to deliver therapy for hereditary diseases. Modalis went public in 2020 (TSE: 4883).
AccuRna harnessed the potential of nano micelle technologies to develop mRNA and other RNA-based therapeutics. Its novel drug delivery platform is capable of delivering both short and long chain nucleic acid therapeutics, currently targeting oncology and rare diseases. AccuRna initiated human trials and was acquired by Nanocarrier (TSE: 4571) in 2020.
Mental Health Technologies offers mental health solution services, doctor career support services, occupational physician cloud services, amongst others. While the top-tier, corporate doctors are only available to larger conglomerates, MHT utilizes its’ exclusive cloud technology to dispatch the same corporate doctors to mid to small companies, allowing for mental health solutions for companies of all sizes. It went public in 2022 (TSE: 9218)
Specialist Doctors offered a Healthcare IT service specializing in a physician database. Their platform connects patients and specialist physicians serving as a network for physicians, an online second-opinion service on medical diagnosis, and as a big-data analysis tool for pharmaceutical manufacturers in Japan. Acquired They were acquired by the Aflac group in 2021.
Chiome Bioscience, born out of the National Institute of Physical and Chemical research at RIKEN in 2005, focuses on therapeutic monoclonal antibody (mAb) development. Its proprietary drug discovery platform employs in vitro mAb production, maximizing antibody accumulation and screening in a remarkably short period of time. Chiome went public (TSE: 4583) in 2012.
BrightPath Bio is a first-generation precision cancer vaccine and diagnostic module for HLA subtyping and tumor antigen profiling. It was founded out of the University of Kurume and went public in 2015.
CellSeed, which was founded in 2001, is one of the pioneering companies that implemented the idea of regenerative medicine. They use temperature-responsive polymer technology to significantly improve cell sheet engineering by removing the need for damaging enzymatic processing. CellSeed collaborates with universities and industry leaders to develop regenerative medical products, reagents, along with cell cultureware. CellSeed went public (TSE: 7776) in 2010.
JMIRI is the first integrated database for medical prescriptions. With exclusive access to over 10 million prescriptions, it offers analysis for pharma and healthcare companies. It was founded by FTI in 2005 and acquired by Intage in 2012.
ProbeX was a research tool company that developed in situ protein-binding probe for protein detection and quantification. It was spun out of the University of Tokyo in 2006 and acquired by Carna Biosciences (TSE: 4572) in 2014.